

their recent update on the management of hypertension in patients with type 2 diabetes.³

It is interesting to note that no competing interests were declared by the authors of the recent letter by Campbell et al.¹ The authors might have not understood the question but, through a quick search of the Internet, it is clear that all the authors, except Dr Chockalingam and Ms Morris, have disclosed (in recent publications) perceived or actual conflicts of interest with several different pharmaceutical companies who manufacture antihypertensive medications.³⁻⁷ We equate these conflicts with “competing interests” and think it is important for readers to be aware of this information while interpreting the work of Campbell et al. We strongly believe that readers could be misled by their original declaration and would respectfully suggest that a correction be published immediately.

—Aaron M. Tejani PharmD

—Jacky T.P. Siu

—Jim M. Wright MD PhD

—Ken Bassett MD PhD

—Vijaya Musini MD MSc

—Barbara Mintzes PhD

—Tom Perry MD

On behalf of the Therapeutics Initiative,
University of British Columbia

Competing interests

None declared

References

1. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension revisited [Letters]. *Can Fam Physician* 2012;58:635-6.
2. Siu JTP, Tejani AM, Musini V, Bassett K, Mintzes B, Wright J. Hypertension control in patients with diabetes [Letters]. *Can Fam Physician* 2012;58:30-5.
3. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension in people with type 2 diabetes. Update on pharmacologic management. *Can Fam Physician* 2011;57:997-1002 (Eng), e347-53 (Fr).
4. Dunford E, Webster J, Woodward M, Czernichow S, Yuan WL, Jenner K, et al. The variability of reported salt levels in fast foods across six countries: opportunities for salt reduction *CMAJ* 2012;184(9):1023-8. Epub 2012 Apr 16.
5. Cardiometabolic Risk Working Group: Executive Committee. Cardiometabolic risk in Canada: a detailed analysis and position paper by the Cardiometabolic Risk Working Group. *Can J Cardiol* 2011;27(2):e1-33.
6. Canadian Cardiovascular Society. *CCS conflicts of interest guidelines and disclosure statements. 2006 CCS Heart Failure Consensus Conference disclosure statements.* Ottawa, ON: Canadian Cardiovascular Society; 2006. Available from: www.hfcc.ca/downloads/important_notices/Disclosure_Statements.pdf. Accessed 2012 Jul 9.
7. Charrois TL, McAlister FA, Cooney D, Lewanczuk R, Kolber MR, Campbell NR, et al. Improving hypertension management through pharmacist prescribing; the rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods. *Science* 2011;6:94.

Correction

In the submission of the letter by Campbell and colleagues,¹ the authors provided statements of competing interests that were inadvertently omitted from the published letter. The competing interests statement should have read as follows:

Competing interests

Dr Gilbert has served on advisory boards, received research grant funding, and given lectures for AstraZeneca, Bristol-Myers Squibb, Merck, and Novartis. Dr Leiter has received research funding from, has provided continuing medical education on behalf of, or has acted as a consultant to AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Sanofi-Aventis, and Servier. Dr Larochelle has received support for continuing education and research grants from Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Pfizer, and Takeda. Dr Tobe has received research grants and speaker’s honoraria from Abbott Laboratories, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck, Novartis, Pfizer, Sanofi-Aventis, and Servier. None of the other authors has any competing interests to declare.

Canadian Family Physician apologizes for any confusion this might have caused.

Reference

1. Campbell NRC, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension revisited [Letters]. *Can Fam Physician* 2012;58:635-6.

Make your views known!

To comment on a particular article, open the article at www.cfp.ca and click on the Rapid Responses link on the right-hand side of the page. Rapid Responses are usually published online within 1 to 3 days and might be selected for publication in the next print edition of the journal. To submit a letter not related to a specific article published in the journal, please e-mail letters.editor@cfpc.ca.

Faites-vous entendre!

Pour exprimer vos commentaires sur un article en particulier, ouvrez l'article à www.cfp.ca et cliquez sur le lien Rapid Responses à droite de la page. Les réponses rapides sont habituellement publiées en ligne dans un délai de 1 à 3 jours et elles peuvent être choisies pour publication dans le prochain numéro imprimé de la revue. Si vous souhaitez donner une opinion qui ne concerne pas spécifiquement un article de la revue, veuillez envoyer un courriel à letters.editor@cfpc.ca.

